Regulatory expertise to support your pharmaceutical products across global markets, from regulatory strategy and product registration to post-approval lifecycle activities.
Entering a new pharmaceutical market requires more than preparing and submitting a regulatory dossier. It involves understanding country-specific regulations, selecting the appropriate registration pathway, ensuring technical documentation meets regulatory expectations, and maintaining compliance throughout the product lifecycle.
RIAR Consulting provides end-to-end pharmaceutical regulatory support to companies seeking to register, commercialise and maintain their products across international markets. Our services support pharmaceutical manufacturers, marketing authorisation holders, contract manufacturers and organisations looking to expand their global presence.
From regulatory strategy and product registration to dossier preparation, submission support, regulatory query management and post-approval lifecycle activities, we help businesses navigate diverse regulatory frameworks with a structured and market-oriented approach.
Our regulatory support covers major pharmaceutical markets, including the United States, United Kingdom, European Union, India and other international regions. We also support medical devices, IVDs and cosmetics in selected markets.
Regulatory compliance does not end once a product receives marketing authorisation. We help companies keep their documentation consistent and manage product requirements across markets throughout the pharmaceutical lifecycle.
Global regulatory pathway assessment, product classification and regulatory positioning, gap analysis and market-entry planning, supported by country-specific regulatory intelligence.
A regulatory pathway assessment and a submission plan for each target market.
Drug substance and drug product information, pharmaceutical development, manufacturing process, specifications, analytical methods and stability documentation.
Quality and CMC documentation reviewed against the expectations of the target authority.
Each market has its own authority, pathways and documentation expectations. Open a market to see how we support it.
The United States is one of the world’s most significant pharmaceutical markets, with a regulatory framework that requires detailed scientific, technical and quality documentation. The US Food and Drug Administration (USFDA) evaluates pharmaceutical products based on their safety, efficacy, quality and manufacturing controls before they can be marketed.
RIAR Consulting supports pharmaceutical companies in understanding and addressing USFDA regulatory requirements throughout the product development, registration and post-approval stages.
RIAR works to help pharmaceutical companies develop a structured regulatory approach for the US market while maintaining alignment with applicable FDA requirements.
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines and healthcare products in the United Kingdom. Pharmaceutical companies entering the UK market must follow applicable marketing authorisation, manufacturing, quality and post-authorisation requirements.
RIAR Consulting provides regulatory support to pharmaceutical companies seeking to introduce new products, maintain existing authorisations or manage regulatory changes within the UK market.
Our objective is to help pharmaceutical companies approach UK regulatory requirements with appropriate documentation, a clear submission strategy and ongoing regulatory oversight.
The European pharmaceutical regulatory framework provides different authorisation routes depending on the product type, its regulatory status and the intended geographical scope of marketing.
The European Medicines Agency (EMA), the European Commission and national competent authorities have distinct roles within this system. Pharmaceutical companies must identify the appropriate authorisation pathway and prepare documentation in line with applicable European requirements. RIAR Consulting supports companies in navigating European regulatory procedures and preparing the technical documentation required for product authorisation and lifecycle management.
RIAR supports companies in developing a coordinated European regulatory approach while considering the specific requirements of the relevant authorisation procedure and national authorities.
The Central Drugs Standard Control Organisation (CDSCO) is India’s central regulatory authority for matters including new drug approvals, clinical trials and the regulation of specified categories of drugs. Companies entering the Indian market must understand the applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, and the New Drugs and Clinical Trials Rules, 2019, as applicable.
RIAR Consulting assists domestic and international pharmaceutical companies in understanding Indian regulatory requirements and preparing documentation for applicable approval, import, manufacturing and lifecycle activities.
RIAR aims to simplify the regulatory process for companies entering or operating in India through structured documentation support and an understanding of the applicable Indian regulatory framework.
The Saudi Food and Drug Authority (SFDA) regulates pharmaceutical products in the Kingdom of Saudi Arabia, including their registration, importation, manufacturing, distribution and ongoing regulatory compliance. RIAR Consulting provides regulatory consulting and documentation support to pharmaceutical manufacturers, marketing authorisation applicants and international companies seeking to register and maintain their products in Saudi Arabia.
The Premarket Tobacco Product Application (PMTA) pathway is administered by the USFDA’s Center for Tobacco Products (CTP). RIAR Consulting provides specialised PMTA and Tobacco Product Master File (TPMF) support to companies preparing regulatory submissions for the US market.
Pharmaceutical companies planning international expansion must navigate different regulatory authorities, country-specific submission requirements, local representation rules and product registration procedures. In addition to the US, UK, European Union and India, our regulatory support can cover other regions and national regulatory frameworks, subject to product type and applicable local requirements.
RIAR’s international regulatory support is designed to help pharmaceutical companies evaluate market opportunities, understand local requirements and coordinate regulatory activities across multiple jurisdictions.
RIAR Consulting supports pharmaceutical, biotech, and life sciences companies with regulatory strategy, compliance, and manufacturing intelligence—helping businesses navigate complex requirements and make more informed decisions throughout the product lifecycle.
The core CTD content is written once, Module 1 for regional administrative requirements and Modules 2 to 5 for quality, non-clinical and clinical information, then adapted to each authority’s format, rules and reviewer expectations.
Most dossiers start like this: modules written by different teams, at different times, to different templates.
Modules aligned: 0 of 5
Every pharmaceutical product, market and regulatory pathway has its own requirements. We start with the product, evaluate the applicable framework and build a clear plan for execution.
We begin by understanding the pharmaceutical product, its development or marketing status, target markets and the company’s regulatory objectives.
We evaluate applicable regulatory requirements, identify the relevant authority and registration pathway, and assess documentation expectations.
We review available technical, quality and administrative documentation to identify gaps that may require additional information, clarification or remediation.
We support the preparation, review, compilation and organisation of regulatory documentation according to the applicable market requirements.
We assist with submission readiness, regulatory correspondence, query management and coordination of technical responses.
We provide lifecycle support for applicable variations, renewals, regulatory changes and documentation maintenance.
Global expansion involves more than submitting the same dossier to different authorities. RIAR brings together regulatory knowledge, technical documentation expertise and market-specific understanding across the product lifecycle.
Support across major international pharmaceutical markets and country-specific regulatory frameworks.
Structured support for CTD/eCTD dossiers, CMC documentation, quality information and regulatory submissions.
Regulatory planning based on the product, target market, applicable authority and relevant approval pathway.
Assistance from initial regulatory assessment and dossier preparation through submission support and post-approval activities.
Support that considers both initial product registration and the regulatory requirements that continue after authorisation.
A separate service group: connecting manufacturing signals, operational processes and critical plant conditions to identify emerging risks and support better-informed manufacturing decisions.
Visibility into relevant facility conditions and equipment operating conditions, where supported by connected systems.
Recognition of unusual patterns in connected operational signals, with AI-assisted advisories that support human assessment.
VERA is advisory only. It does not write to or control plant systems; decisions remain with authorised personnel.
Pharmaceutical regulatory support for the Saudi Arabian market, alongside medical device, IVD and cosmetic registrations.
Scientific and regulatory support for Premarket Tobacco Product Applications and Tobacco Product Master Files.
RIAR’s Continuous Intelligence Manufacturing System for pharmaceutical manufacturing environments.
Whether you are preparing a new regulatory submission, expanding into an international market, managing post-approval changes or addressing regulatory documentation gaps, RIAR Consulting can support your regulatory objectives.